• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Apoptosis in Oncology Drug Pipeline Update 2013 Product Image

Apoptosis in Oncology Drug Pipeline Update 2013

  • Published: April 2013
  • Region: World
  • Bioseeker

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells. There are today 282 companies plus partners developing 277 apoptotic drugs in 1179 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 161 drugs. Apoptosis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 201 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 173 out of the 194 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 54 classifications of molecular function and with pathway referrals to BioCarta, KEGG. NCI-Nature and NetPath.

How READ MORE >

Format Properties
Electronic (Online Access) The report will be emailed to you. Online access is provided for this product. This is a single user license, allowing one specific user access to the product.
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos